Turner Marcus L, Taha Abu M, Yonamine Sean, Yu Yinxi, Saifee Murtaza, Yang Mike, Ying Gui-Shuang, Han Ying, Oatts Julius T
Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Clin Ophthalmol. 2022 Sep 29;16:3193-3203. doi: 10.2147/OPTH.S381368. eCollection 2022.
To determine the change in Humphrey visual field and clinical parameters after minimally invasive glaucoma surgery combined with cataract surgery.
Patients undergoing minimally invasive glaucoma surgery combined with cataract surgery in a multicenter retrospective case series between 2013 and 2021 with reliable preoperative and 12 to 18 month postoperative visual field measurements were included. Devices included iStent, XEN, and Hydrus. Clinical parameters were compared with a generalized linear model with generalized estimating equations between preoperative and postoperative visits including best corrected visual acuity, intraocular pressure, number of glaucoma medications and visual fields. Visual field metrics included mean deviation (MD), pattern standard deviation (PSD), visual field index (VFI), and Collaborative Initial Glaucoma Treatment Study (CIGTS) score of total deviation probability and pattern deviation probability.
Forty-four eyes from 39 patients were included. During the follow up period, visual acuity improved from 0.23±0.17 to 0.10±0.14 logMAR (mean ± standard deviation, <0.001), number of glaucoma medications was reduced from 2.68±1.06 to 1.46±1.32 (<0.001), and intraocular pressure decreased from 17.08±4.23 mmHg to 14.92±3.13 mmHg (=0.003). Differences across devices were negligible. The only significant difference was a greater reduction in number of glaucoma medications in the XEN group (<0.001). There were no significant changes in the global parameters of VFI, MD, PSD, or CIGTS.
Overall, minimally invasive glaucoma surgery combined with cataract surgery appears to be effective at stabilizing visual field function, reducing intraocular pressure, reducing number of glaucoma medications, and improving visual acuity over a 12 to 18 month follow-up period across MIGS devices.
确定微创青光眼手术联合白内障手术后汉弗莱视野及临床参数的变化。
纳入2013年至2021年间在多中心回顾性病例系列中接受微创青光眼手术联合白内障手术的患者,这些患者术前和术后12至18个月的视野测量结果可靠。所使用的器械包括iStent、XEN和Hydrus。采用广义估计方程的广义线性模型对术前和术后访视时的临床参数进行比较,包括最佳矫正视力、眼压、青光眼药物使用数量和视野。视野指标包括平均偏差(MD)、模式标准差(PSD)、视野指数(VFI)以及总偏差概率和模式偏差概率的协作初始青光眼治疗研究(CIGTS)评分。
纳入了39例患者的44只眼。在随访期间,视力从0.23±0.17 logMAR提高到0.10±0.14 logMAR(平均值±标准差,P<0.001),青光眼药物使用数量从2.68±1.06减少到1.46±1.32(P<0.001),眼压从17.08±4.23 mmHg降至14.92±3.13 mmHg(P = 0.003)。不同器械之间的差异可忽略不计。唯一显著的差异是XEN组青光眼药物使用数量减少得更多(P<0.001)。VFI、MD、PSD或CIGTS的整体参数没有显著变化。
总体而言,在12至18个月的随访期内,微创青光眼手术联合白内障手术似乎能有效稳定视野功能、降低眼压、减少青光眼药物使用数量并提高视力,涵盖多种微创青光眼手术器械。